Johnson & Johnson Business Combination, Acquisition Related Costs
Johnson & Johnson (JNJ) reported Business Combination, Acquisition Related Costs of $100.00 million for the 6-month period ending 2026-06-28, per its 10-Q filed 2026-07-23.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:BusinessCombinationAcquisitionRelatedCosts · last filed 2026-07-23
- Johnson & Johnson business combination, acquisition related costs for the quarter ending 2025-06-29 was $200.00M.
- Johnson & Johnson business combination, acquisition related costs for the quarter ending 2023-10-01 was $0.00.
- Johnson & Johnson business combination, acquisition related costs for the quarter ending 2023-07-02 was -$200.00M.
- Johnson & Johnson business combination, acquisition related costs for the quarter ending 2023-04-02 was $300.00M.
- Johnson & Johnson business combination, acquisition related costs for fiscal 2023 was $300.00M.
| Period end | Business Combination, Acquisition Related Costs 3 month | Business Combination, Acquisition Related Costs 6 month | Business Combination, Acquisition Related Costs 9 month | Business Combination, Acquisition Related Costs 12 month |
|---|---|---|---|---|
| 2026-06-28 | $100.00M 10-Q · filed 2026-07-23 | |||
| 2025-06-29 | $200.00M 10-Q · filed 2025-07-24 | $200.00M 10-Q · filed 2026-07-23 | ||
| 2023-10-01 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-27 | -$200.00M derived: sum of 2 quarters · filed 2023-10-27 | $100.00M 10-Q · filed 2023-10-27 | |
| 2023-07-02 | -$200.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-07-31 | $100.00M 10-Q · filed 2023-07-31 | ||
| 2023-04-02 | $300.00M 10-Q · filed 2023-10-27 | |||
| 2023-01-01 | $300.00M 10-K · filed 2025-02-13 | |||
| 2019-12-29 | $90.00M 10-K · filed 2020-02-18 | $197.00M derived: sum of 2 quarters · filed 2020-02-18 | $252.00M derived: sum of 3 quarters · filed 2020-02-18 | $319.00M derived: sum of 4 quarters · filed 2020-02-18 |
| 2019-09-29 | $107.00M 10-K · filed 2020-02-18 | $162.00M derived: sum of 2 quarters · filed 2020-02-18 | $229.00M derived: sum of 3 quarters · filed 2020-02-18 | |
| 2019-06-30 | $55.00M 10-K · filed 2020-02-18 | $122.00M derived: sum of 2 quarters · filed 2020-02-18 | ||
| 2019-03-31 | $67.00M 10-K · filed 2020-02-18 | |||
| 2017-12-31 | $217.00M 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |